J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364

Similar documents
DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018

DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019

MDwise Self-Administered Codes for Medical

Medicare Part B Covered Medications

The following are J Code requirements

Drug Name Tier Drug Name Tier

Injections Requiring Prior Authorization

Table III: 2019 Medicare Drug Fee Schedule* CY st Quarter Average Sales Price (ASP) Data Plus 6 Percent

A9542 A9543 A9545 A9699 J0120 J0128 J0129 J0130

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

Modular Program Report

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Subject: Palonosetron Hydrochloride (Aloxi )

Injectables/Medications Administered Under the Medical Benefit Authorization NOT Required List Effective 04/01/2017

MASCC Guidelines for Antiemetic control: An update

MEDICAL POLICY No R10 INFUSION SERVICES & EQUIPMENT

Drug Use Evaluation: Physician Administered Drugs (PADs)

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

Guideline Update on Antiemetics

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Medicare Part C Medical Coverage Policy

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

Highmark List of Procedure Codes Requiring NDC Effective 12/01/2017

Guidelines for the Use of Anti-Emetics with Chemotherapy

MEDICAL MANAGEMENT POLICY

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

NOTICES DEPARTMENT OF HEALTH

Drug Class Prior Authorization Criteria Immune Globulins

LCD for Nebulizers (L27226)

Modular Program Report

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

Intravenous Immune Globulin (IVIg)

High Risk Medications

LCD for Nebulizers (L11488)

1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000

IHCP banner page INDIANA HEALTH COVERAGE PROGRAMS BR FEBRUARY 16, 2016

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

Managements of Chemotherpay Induded Nausea and Vomiting

CURRENT DRUG SHORTAGES (through February 22, 2013) CURRENT & ONGOING SHORTAGES CRITICAL SHORTAGES

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Immune Globulin. Prior Authorization

TennCare Program TN MAC Price Change List As of: 03/30/2017

Part B payment for drugs in Medicare 0

External Infusion Pumps

Cost-Motivated Treatment Changes in Medicare Part B:


ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

LIST OF DRUGS / MEDICINES ITEMS FOR THE YEAR (Non-Prequalified Items) A: Injection Antimicrobials Sr. No.

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Our mission is better health care outcomes.

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

Clinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:

Antiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue

CPT / HCPCS Code. Drug Description

IMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical

See Important Reminder at the end of this policy for important regulatory and legal information.

Rajasthan Medical Services Corporation Limited, Jaipur

MEDICAL NECESSITY GUIDELINE

Measure Abbreviation: PONV 01 (MIPS 430)

See Important Reminder at the end of this policy for important regulatory and legal information.

A CMS Program Safeguard Contractor. The following list identifies changes to level II Healthcare Common Procedure Coding System (HCPCS) for 2008.

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Active Pharmaceutical Ingredient (API) List List Updated March 1st, 2019

Welcome. Coding uidelines Coding Guidelines Coding. Coding Guidelines Coding Guidelines. Contact Us. Edition #1 March 2018

OFFERâ S INJECTABLES

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009

Product Name Strength Dosage Form Therapeutic Area Dossier Status. Aceclofenac 100mg Film coated Tablets Analgesia-inflammation Approved

Corporate Medical Policy

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

ADULT Updated: September 4, 2018

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

Part B payment for drugs in Medicare 0

Emetogenicity level 1. Emetogenicity level 2

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients

Measure Abbreviation: PONV 01 (MIPS 430)

Medicare Part C Medical Coverage Policy

To help doctors give their patients the best possible care, the American

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

Northern Cancer Alliance

Drug Infusion Site of Care Policy

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue

Job title: Consultant Pharmacist/Advanced Practice Pharmacist

Riesbeck's Pharmacy Reward Club Generic Medication List February 2018 $4 30 Day Supply

Generic (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists

RITUXAN (rituximab and hyaluronidase human)

Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice

See Important Reminder at the end of this policy for important regulatory and legal information.

Our mission is better health care outcomes.

Riesbeck's Pharmacy Reward Club Generic Medication List October 2017

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

COMMERCIAL APIs. S. No Molecule Name Therapeutic Category USDMF EDMF CEP IH

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

Transcription:

G0333 INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.470 J0285 INJECTION, AMPHOTERICIN B 50 MG $10.280 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $21.850 J0288 INJECTION, AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX 10 MG $15.200 J0289 INJECTION, AMPHOTERICIN B LIPOSOME 10 MG $35.800 J0895 INJECTION, DEFEROXAMINE MESYLATE 500 MG $15.630 J1170 INJECTION, HYDROMORPHONE UP TO 4 MG $1.490 J1250 INJECTION, DOBUTAMINE HYDROCHLORIDE 250 MG $4.740 J1265 INJECTION, DOPAMINE HCL 40 MG $0.620 J1325 INJECTION, EPOPROSTENOL 0.5 MG $12.640 J1455 INJECTION, FOSCARNET SODIUM 1000 MG $13.070 J1459 INJECTION, IMMUNE GLOBULIN (PRIVIGEN), 500 MG $36.752 J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $38.220 J1557 INJECTION, IMMUNE GLOBULIN, (GAMMAPLEX), 500 MG $36.232 J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364 J1561 INJECTION, IMMUNE GLOBULIN, (GAMUNEX- C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID) 500 MG $39.504 J1561JB INJECTION, IMMUNE GLOBULIN, (GAMUNEX- C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID) [JB modifier indicates drug being administered 500 MG $46.170 subcutaneously] J1562 INJECTION, IMMUNE GLOBULIN (VIVAGLOBIN) 100 MG $11.400 J1566 INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, LYOPHILIZED (E.G. POWDER), NOT OTHERWISE 500 MG $30.043 SPECIFIED J1568 INJECTION, IMMUNE GLOBULIN, (OCTAGAM), 500 MG $30.498 J1569 INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G. LIQUID) 500 MG $39.165 J1569JB INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G. LIQUID) [JB modifier indicates drug being administered subcutaneously] 500 MG $52.497 J1570 INJECTION, GANCICLOVIR SODIUM 500 MG $35.250 J1572 INJECTION, IMMUNE GLOBULIN, (FLEBOGAMMA/FLEBOGAMMA DIF), INTRAVENOUS, NON- 500 MG $36.326 LYOPHILIZED (E.G. LIQUID) J1815 INJECTION, INSULIN 5 UNITS $0.639 J1817 INSULIN FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) 50 UNITS $2.800 J2175 INJECTION, MEPERIDINE HYDROCHLORIDE 100 MG $0.560 J2260 INJECTION, MILRINONE LACTATE 5 MG $51.580 J2270 INJECTION, MORPHINE SULFATE UP TO 10 MG $0.710 J2271 INJECTION, MORPHINE SULFATE 100 MG $11.070 Page 1 of 5 03/27/2015

J2275 INJECTION, MORPHINE SULFATE (PRESERVATIVE-FREE STERILE SOLUTION) 10 MG $4.390 J2278 INJECTION, ZICONOTIDE 1 MCG $6.935 PENTAMIDINE ISETHIONATE, INHALATION SOLUTION, J2545 FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, 300 MG $85.818 J2791 INJECTION, RHO(D) IMMUNE GLOBULIN (HUMAN), (RHOPHYLAC), INTRAMUSCULAR OR INTRAVENOUS 100 IU $4.753 J2920 INJECTION, METHYLPREDNISOLONE SODIUM SUCCINATE UP TO 40 MG $1.785 J2930 INJECTION, METHYLPREDNISOLONE SODIUM SUCCINATE UP TO 125 MG $2.607 J3010 INJECTION, FENTANYL CITRATE 0.1 MG $0.700 J3285 INJECTION, TREPROSTINIL 1 MG $61.750 J7500 AZATHIOPRINE, ORAL 50 MG $0.269 J7501 AZATHIOPRINE, PARENTERAL 100 MG $217.300 J7502 CYCLOSPORINE, ORAL 100 MG $3.109 J7504 LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE GLOBULIN, EQUINE, PARENTERAL 250 MG $742.892 J7506 PREDNISONE, ORAL 5 MG $0.079 J7507 TACROLIMUS, IMMEDIATE RELEASE, ORAL 1 MG $1.565 J7508 TACROLIMUS, EXTENDED RELEASE, ORAL 0.1 MG $0.403 J7509 METHYLPREDNISOLONE, ORAL 4 MG $0.603 J7510 PREDNISOLONE, ORAL 5 MG $0.109 J7511 LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE GLOBULIN, RABBIT, PARENTERAL 25 MG $541.167 J7515 CYCLOSPORINE, ORAL 25 MG $0.828 J7516 CYCLOSPORINE, PARENTERAL 250 MG $38.687 J7517 MYCOPHENOLATE MOFETIL, ORAL 250 MG $1.123 J7518 MYCOPHENOLIC ACID, ORAL 180 MG $4.136 J7520 SIROLIMUS, ORAL 1 MG $14.542 J7525 TACROLIMUS, PARENTERAL 5 MG $136.281 J7527 EVEROLIMUS, ORAL 0.25 MG $6.847 ARFORMOTEROL, INHALATION SOLUTION, FDA J7605KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 15 MCG $6.141 FORMOTEROL FUMARATE, INHALATION SOLUTION, FDA J7606KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 20 MCG $6.914 ACETYLCYSTEINE, INHALATION SOLUTION, FDA- J7608KO APPROVED FINAL PRODUCT, NON-COMPOUNDED, 1 GM $1.939 ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED J7611 FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED 1 MG $0.100 THROUGH DME, CONCENTRATED FORM LEVALBUTEROL, INHALATION SOLUTION, FDA- J7612 APPROVED FINAL PRODUCT, NON-COMPOUNDED, 0.5 MG $0.185 ADMINISTERED THROUGH DME, CONCENTRATED FORM ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED J7613KO FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED 1 MG $0.052 THROUGH DME, UNIT DOSE Page 2 of 5 03/27/2015

J7614KO J7620 LEVALBUTEROL, INHALATION SOLUTION, FDA- APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE ALBUTEROL, UP TO 2.5 MG AND IPRATROPIUM BROMIDE, UP TO 0.5 MG, FDA-APPROVED FINAL PRODUCT, NON- COMPOUNDED, ADMINISTERED THROUGH DME 0.5 MG $0.094 1 UNIT $0.180 J7626KO BUDESONIDE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED UP TO 0.5 MG $5.102 J7631KO CROMOLYN SODIUM, INHALATION SOLUTION, FDA- APPROVED FINAL PRODUCT, NON-COMPOUNDED, 10 MG $0.435 J7639KO DORNASE ALPHA, INHALATION SOLUTION, FDA- APPROVED FINAL PRODUCT, NON-COMPOUNDED, 1 MG $32.799 J7644KO IPRATROPIUM BROMIDE, INHALATION SOLUTION, FDA- APPROVED FINAL PRODUCT, NON-COMPOUNDED, 1 MG $0.234 J7669KO METAPROTERENOL SULFATE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, 10 MG $0.435 TOBRAMYCIN, INHALATION SOLUTION, FDA-APPROVED J7682KO FINAL PRODUCT, NON-COMPOUNDED, UNIT DOSE FORM, 300 MG $108.965 ADMINISTERED THROUGH DME TREPROSTINIL, INHALATION SOLUTION, FDA-APPROVED J7686KO FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED 1.74 MG $460.436 J8501 APREPITANT, ORAL 5 MG $7.445 J8520 CAPECITABINE, ORAL 150 MG $10.064 J8521 CAPECITABINE, ORAL 500 MG $33.560 J8530 CYCLOPHOSPHAMIDE; ORAL 25 MG $0.995 J8540 DEXAMETHASONE, ORAL 0.25 MG $0.159 J8610 METHOTREXATE; ORAL 2.5 MG $1.035 J8650 NABILONE, ORAL 1 MG $28.419 J9000 INJECTION, DOXORUBICIN HYDROCHLORIDE 10 MG $12.540 J9040 INJECTION, BLEOMYCIN SULFATE 15 UNITS $289.370 J9065 INJECTION, CLADRIBINE 1 MG $61.720 J9070 CYCLOPHOSPHAMIDE 100 MG $5.730 J9100 INJECTION, CYTARABINE 100 MG $8.190 J9181 INJECTION, ETOPOSIDE 10 MG $1.710 J9190 INJECTION, FLUOROURACIL 500 MG $2.070 J9200 INJECTION, FLOXURIDINE 500 MG $136.800 J9208 INJECTION, IFOSFAMIDE 1 GM $150.380 J9355 INJECTION, TRASTUZUMAB 10 MG $58.130 J9360 INJECTION,VINBLASTINE SULFATE 1 MG $4.100 J9370 VINCRISTINE SULFATE 1 MG $33.980 Page 3 of 5 03/27/2015

Q0162 Q0163 Q0164 Q0166 Q0167 Q0169 Q0173 Q0174 Q0175 Q0177 ONDANSETRON, ORAL, FDA APPROVED PRESCRIPTION SUBSTITUTE FOR AN IV ANTI-EMETIC AT THE TIME OF CHEMOTHERAPY TREATMENT, NOT TO EXCEED A 48 1 MG $0.072 DIPHENHYDRAMINE HYDROCHLORIDE, ORAL, FDA COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI- 50 MG $0.204 PROCHLORPERAZINE MALEATE, ORAL, FDA APPROVED THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT 5MG $0.031 GRANISETRON HYDROCHLORIDE, ORAL, FDA COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI- 1 MG $1.773 TO EXCEED A 24 DRONABINOL, ORAL, FDA APPROVED PRESCRIPTION SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF 2.5 MG $3.546 CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 PROMETHAZINE HYDROCHLORIDE, ORAL, FDA COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI- 12.5 MG $0.022 TRIMETHOBENZAMIDE HYDROCHLORIDE, ORAL, FDA COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI- 250 MG $0.349 THIETHYLPERAZINE MALEATE, ORAL, FDA APPROVED THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT 10 MG TBD* PERPHENAZINE, ORAL, FDA APPROVED PRESCRIPTION SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF 4 MG $1.337 CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HYDROXYZINE PAMOATE, ORAL, FDA APPROVED THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT 25 MG $0.133 Page 4 of 5 03/27/2015

Q0180 Q0510 Q0511 Q0512 DOLASETRON MESYLATE, ORAL, FDA APPROVED THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT A 24 PHARMACY SUPPLY FEE FOR INITIAL IMMUNOSUPPRESSIVE DRUG(S), FIRST MONTH FOLLOWING TRANSPLANT PHARMACY SUPPLY FEE FOR ORAL ANTI-CANCER, ORAL ANTI-EMETIC OR IMMUNOSUPPRESSIVE DRUG(S); FOR THE FIRST PRESCRIPTION IN A 30-DAY PERIOD PHARMACY SUPPLY FEE FOR ORAL ANTI-CANCER, ORAL ANTI-EMETIC OR IMMUNOSUPPRESSIVE DRUG(S); FOR A SUBSEQUENT PRESCRIPTION IN A 30-DAY PERIOD 100 MG $70.179 $50.000 $24.000 $16.000 Q0513 PER 30 DAYS $33.000 Q0514 PER 90 DAYS $66.000 Q4074 ILOPORST, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED UP TO 20 MCG $81.620 NDC number BUSULFAN, ORAL 2 MG $10.808 NDC number CAPECITABINE, ORAL 150 MG $10.064 NDC number CAPECITABINE, ORAL 500 MG $33.560 NDC number CYCLOPHOSPHAMIDE, ORAL 25 MG $0.995 NDC number CYCLOPHOSPHAMIDE, ORAL 50 MG $1.990 NDC number ETOPOSIDE, ORAL 50 MG $58.156 NDC number FLUDARABINE PHOSPHATE, ORAL 10 MG TBD* NDC number MELPHALAN, ORAL 2 MG $9.076 NDC number METHOTREXATE, ORAL 2.5 MG $1.035 NDC number METHOTREXATE, ORAL 5 MG $2.070 NDC number METHOTREXATE, ORAL 7.5 MG $3.105 NDC number METHOTREXATE, ORAL 10 MG $4.140 NDC number METHOTREXATE, ORAL 15 MG $6.210 NDC number TEMOZOLOMIDE, ORAL 5 MG $6.943 NDC number TEMOZOLOMIDE, ORAL 20 MG $27.772 NDC number TEMOZOLOMIDE, ORAL 100 MG $138.860 NDC number TEMOZOLOMIDE, ORAL 140 MG $194.404 NDC number TEMOZOLOMIDE, ORAL 180 MG $249.948 NDC number TEMOZOLOMIDE, ORAL 250 MG $347.150 NDC number TOPOTECAN, ORAL 0.25 MG $91.929 *To Be Developed (TBD) indicates the claim will be developed for an invoice on the drug billed. Page 5 of 5 03/27/2015